Golf Clap for Allergan
Allergan (NYS: AGN) reported earnings on Feb. 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Allergan met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share increased.
Gross margins expanded, operating margins grew, net margins dropped.
Allergan booked revenue of $1.40 billion. The 21 analysts polled by S&P Capital IQ looked for revenue of $1.41 billion. Sales were 7.1% higher than the prior-year quarter's $1.31 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $1.00. The 25 earnings estimates compiled by S&P Capital IQ averaged $1.00 per share on the same basis. GAAP EPS of $0.90 for Q4 were 5.9% higher than the prior-year quarter's $0.85 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 87.0%, 100 basis points better than the prior-year quarter. Operating margin was 29.2%, 120 basis points better than the prior-year quarter. Net margin was 20.0%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.38 billion. On the bottom line, the average EPS estimate is $0.90.
Next year's average estimate for revenue is $5.89 billion. The average EPS estimate is $4.20.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 385 members out of 408 rating the stock outperform, and 23 members rating it underperform. Among 128 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 123 give Allergan a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $90.74.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Allergan the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Allergan to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.